Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q12899
UPID:
TRI26_HUMAN
Alternative names:
Acid finger protein; RING finger protein 95; Zinc finger protein 173
Alternative UPACC:
Q12899; A6NG96; Q5SRL2
Background:
Tripartite motif-containing protein 26, also known as Acid finger protein, RING finger protein 95, and Zinc finger protein 173, plays a pivotal role in immune response and DNA repair. It regulates IFN-beta production, oxidative stress responses, and antiviral mechanisms, impacting DNA glycosylases NEIL1, NEIL3, and NTH1 levels. It also influences LPS-mediated inflammatory responses and ferroptosis by ubiquitinating various proteins for degradation.
Therapeutic significance:
Understanding the role of Tripartite motif-containing protein 26 could open doors to potential therapeutic strategies.